Stock of Crinetics Pharmaceuticals, Inc. (CRNX) is rising over 17 percent on Tuesday following the announcement of positive results from Phase 3 PATHFNDR-2 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.
The company stated that statistical significance of primary and secondary endpoints were met in the study.
Crinetics also said that it plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2024.
Currently, Crinetics' stock is rising 17.32 percent, to $44.50 over the previous close of $37.93 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.